Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 52.97 Million USD | 169.07% |
| 2022 | -76.69 Million USD | 62.62% |
| 2021 | -205.19 Million USD | -44.19% |
| 2020 | -142.3 Million USD | -77.81% |
| 2019 | -80.03 Million USD | 36.34% |
| 2018 | -125.71 Million USD | -1157.94% |
| 2017 | -9.99 Million USD | 23.24% |
| 2016 | -13.01 Million USD | 69.83% |
| 2015 | -43.15 Million USD | -298.89% |
| 2014 | -10.81 Million USD | 27.95% |
| 2013 | -15.01 Million USD | -91.84% |
| 2012 | -7.82 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.8 Million USD | -127.48% |
| 2024 Q2 | 1.35 Million USD | 128.09% |
| 2023 Q2 | -8.55 Million USD | -263.55% |
| 2023 Q1 | -2.35 Million USD | 71.76% |
| 2023 FY | 52.97 Million USD | 169.07% |
| 2023 Q4 | -2.11 Million USD | -103.2% |
| 2023 Q3 | 66 Million USD | 871.27% |
| 2022 Q1 | -31.88 Million USD | 38.15% |
| 2022 FY | -76.69 Million USD | 62.62% |
| 2022 Q4 | -8.33 Million USD | -109.31% |
| 2022 Q3 | 89.5 Million USD | 171.05% |
| 2022 Q2 | -125.98 Million USD | -295.07% |
| 2021 Q2 | -33.42 Million USD | 27.57% |
| 2021 Q3 | -74.06 Million USD | -121.57% |
| 2021 FY | -205.19 Million USD | -44.19% |
| 2021 Q4 | -51.55 Million USD | 30.39% |
| 2021 Q1 | -46.15 Million USD | -13.68% |
| 2020 Q1 | -19.14 Million USD | -50.55% |
| 2020 Q2 | -52.66 Million USD | -175.08% |
| 2020 Q4 | -40.59 Million USD | -35.78% |
| 2020 Q3 | -29.89 Million USD | 43.23% |
| 2020 FY | -142.3 Million USD | -77.81% |
| 2019 Q1 | -18.06 Million USD | -20.61% |
| 2019 Q4 | -12.71 Million USD | 7.83% |
| 2019 Q3 | -13.79 Million USD | 61.08% |
| 2019 Q2 | -35.45 Million USD | -96.2% |
| 2019 FY | -80.03 Million USD | 36.34% |
| 2018 FY | -125.71 Million USD | -1157.94% |
| 2018 Q4 | -14.98 Million USD | 18.72% |
| 2018 Q3 | -18.43 Million USD | 20.71% |
| 2018 Q2 | -23.24 Million USD | 66.34% |
| 2018 Q1 | -69.05 Million USD | -2826.38% |
| 2017 Q1 | -3.01 Million USD | -52.82% |
| 2017 FY | -9.99 Million USD | 23.24% |
| 2017 Q4 | -2.35 Million USD | -30.64% |
| 2017 Q3 | -1.8 Million USD | 35.81% |
| 2017 Q2 | -2.81 Million USD | 6.63% |
| 2016 Q2 | -2.65 Million USD | 55.9% |
| 2016 Q4 | -1.97 Million USD | 16.53% |
| 2016 FY | -13.01 Million USD | 69.83% |
| 2016 Q3 | -2.36 Million USD | 11.1% |
| 2016 Q1 | -6.02 Million USD | 36.66% |
| 2015 Q1 | -6.9 Million USD | -138.29% |
| 2015 FY | -43.15 Million USD | -298.89% |
| 2015 Q4 | -9.51 Million USD | 44.88% |
| 2015 Q3 | -17.26 Million USD | -82.14% |
| 2015 Q2 | -9.47 Million USD | -37.31% |
| 2014 Q2 | -2.27 Million USD | -42.27% |
| 2014 Q1 | -1.6 Million USD | 42.59% |
| 2014 FY | -10.81 Million USD | 27.95% |
| 2014 Q4 | -2.89 Million USD | 28.32% |
| 2014 Q3 | -4.04 Million USD | -77.27% |
| 2013 FY | -15.01 Million USD | -91.84% |
| 2013 Q4 | -2.79 Million USD | 0.0% |
| 2012 FY | -7.82 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 4067.184% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 858.703% |
| Nascent Biotech, Inc. | -2.08 Million USD | 2637.695% |
| Rebus Holdings, Inc. | -1.02 Million USD | 5294.02% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 18.66% |
| Qrons Inc. | -789.34 Thousand USD | 6811.75% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 8477.358% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 184.632% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 12851.306% |
| Skye Bioscience, Inc. | -37.64 Million USD | 240.734% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 170.674% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 905.628% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 19477.693% |
| SQZ Biotechnologies Company | -79.46 Million USD | 166.67% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 1931.666% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 3010.09% |
| Mesoblast Limited | -87.95 Million USD | 160.234% |
| Marizyme, Inc. | -65.34 Million USD | 181.073% |
| Genus plc | 7.9 Million USD | -570.62% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 586.414% |
| Pharming Group N.V. | -10.54 Million USD | 602.266% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 2541.638% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 1527.915% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 699.039% |
| ContraFect Corporation | -65.15 Million USD | 181.315% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 1184.288% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 3166.882% |
| IMV Inc. | -36.48 Million USD | 245.205% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 757.334% |
| MultiCell Technologies, Inc. | -380.07 USD | 13939374.344% |
| ONE Bio Corp. | 8.67 Million USD | -510.595% |
| Accustem Sciences Inc. | -3.74 Million USD | 1514.124% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 202.49% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 4281.01% |
| Q BioMed Inc. | -2.05 Million USD | 2681.706% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 1519.207% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 2325.195% |
| Biomind Labs Inc. | -1.21 Million USD | 4462.857% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 188.704% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 1808.026% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 770.358% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 2817.919% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 353859.348% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 433.801% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 1010.722% |
| GB Sciences, Inc. | -1.36 Million USD | 3990.717% |
| Alpha Cognition Inc. | -13.77 Million USD | 484.67% |
| HST Global, Inc. | -146.21 Thousand USD | 36334.868% |
| CSL Limited | 2.64 Billion USD | 97.995% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 3119.14% |
| Halberd Corporation | -79.67 Thousand USD | 66593.047% |
| Enzolytics Inc. | -2.17 Million USD | 2533.766% |
| Agentix Corp. | -1.37 Million USD | 3955.23% |
| Resverlogix Corp. | -3.61 Million USD | 1567.562% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 1770.505% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 117.956% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -53960.204% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -665.085% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 1433.478% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 1850.715% |
| AVAX Technologies, Inc. | -6.41 Million USD | 926.035% |
| Zenith Capital Corp. | -10.59 Million USD | 599.991% |
| Genscript Biotech Corporation | -95.47 Million USD | 155.489% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 228045.099% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 1377.854% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 87754.641% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 2742.193% |
| Kadimastem Ltd | -3.3 Million USD | 1701.833% |
| Helix BioMedix, Inc. | -1.05 Million USD | 5116.68% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 1487.248% |
| BioStem Technologies, Inc. | -8.48 Million USD | 724.533% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 12103.335% |
| LadRx Corporation | 400.44 Thousand USD | -13130.098% |
| Cell Source, Inc. | -5.32 Million USD | 1095.619% |
| Regen BioPharma, Inc. | 1.02 Million USD | -5076.217% |
| Regen BioPharma, Inc. | 1.02 Million USD | -5076.217% |
| NovAccess Global Inc. | -4.76 Million USD | 1210.86% |
| Affymax, Inc. | -14.42 Million USD | 467.298% |
| Itoco Inc. | -1.86 Million USD | 2934.625% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 1292.54% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 3274.296% |
| Mobile Lads Corp. | -2.26 Million USD | 2440.794% |
| CytoDyn Inc. | -49.84 Million USD | 206.296% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 67134.024% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 23323.468% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 5726.911% |
| SYBLEU INC | -180.3 Thousand USD | 29483.153% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 3385.037% |
| International Stem Cell Corporation | -131 Thousand USD | 40541.985% |
| Bioxytran, Inc. | -4.28 Million USD | 1337.827% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 97717.556% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 2193.827% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 210.208% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 2606.102% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 6884.464% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 1772.317% |
| Neutra Corp. | -233.46 Thousand USD | 22792.481% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 361.096% |
| PureTech Health plc | -65.69 Million USD | 180.641% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 349.119% |
| IXICO plc | -1.17 Million USD | 4597.368% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 633.686% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 192.737% |
| CSL Limited | 2.64 Billion USD | 97.995% |
| Cellectis S.A. | -103.17 Million USD | 151.349% |